Allurion Technologies Inc. (ALUR)
| Market Cap | 13.66M -21.4% |
| Revenue (ttm) | 12.60M -55.5% |
| Net Income | -33.35M |
| EPS | -3.45 |
| Shares Out | 15.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,376 |
| Average Volume | 40,299 |
| Open | 0.7300 |
| Previous Close | 0.9100 |
| Day's Range | 0.7300 - 0.9100 |
| 52-Week Range | 0.2300 - 3.3300 |
| Beta | -0.21 |
| RSI | 56.55 |
| Earnings Date | May 20, 2026 |
About Allurion Technologies
Allurion Technologies Inc. focuses on developing a weight loss platform for overweight people in Spain, France, Turkey, and internationally. Its Allurion Program platform offers the Allurion Smart Capsule, a swallowable and procedure-less intragastric balloon for weight loss, and access to the Allurion Virtual Care Suite, a digital therapeutic that combines AI-powered remote patient monitoring tools with a behavior change program. The company is headquartered in Natick, Massachusetts. [Read more]
Financial Performance
In 2025, Allurion Technologies's revenue was $15.23 million, a decrease of -52.57% compared to the previous year's $32.11 million. Losses were -$28.76 million, 299.5% more than in 2024.
Financial StatementsNews
Allurion Technologies Quarterly report: Q1 2026
Allurion Technologies has published its Q1 2026 quarterly earnings report on May 15, 2026.
Allurion Technologies treats first commercial patients in the U.S.
Allurion Technologies (ALUR) announced the commercial treatment of its first patients in the United States-an inflection point that formally launches the company into the world’s largest and most dyna...
Allurion Treats First Commercial Patients in the United States, Marking Major Milestone
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in ...
Allurion Technologies Annual report: Q4 2025
Allurion Technologies has published its Q4 2025 annual report on March 30, 2026.
Allurion Technologies appeals NYSE decision to initiate delisting proceedings
Allurion Technologies (ALUR) announced that it has appealed the decision by the New York Stock Exchange to initiate delisting proceedings against Allurion’s securities pursuant to Section 802.01B of t...
Allurion Advances Plan to Regain Listing Compliance
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (the “Company”) (OTCID: ALUR), a pioneer in metabolically healthy weight loss, announced today that it has appealed the decision b...
Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced that it has officially begun training and on‑boardi...
NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities en...
Allurion Technologies to appeal NYSE notice of delisting
Allurion Technologies (ALUR) has received notice from the NYSE that it intends to initiate delisting proceedings against Allurion after the company was unable to demonstrate that it had regained compl...
Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, has received notice from the New York Stock Exchange (NYSE) th...
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agre...
Allurion Technologies upgraded to Buy from Neutral at Chardan
Chardan analyst Keay Nakae upgraded Allurion Technologies (ALUR) to Buy from Neutral with a $3 price target The company obtained FDA approval for its gastric balloon system, featuring the Allurion…
Allurion Technologies receives FDA approval for gastric balloon system
Allurion Technologies (ALUR) announced that the U.S. Food and Drug Administration has approved the premarket approval application for the Allurion Gastric Balloon System, featuring the Allurion Smart ...
Allurion Receives U.S. FDA Approval
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and Drug Administration (FDA) has...
Allurion announces partnership with Bionut to offer discounted Mounjaro
Allurion Technologies (ALUR) announced a partnership with Bionut to provide patients with access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule. Previously reported r...
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a partnership with Bionut, a leader in obesity care ...
Allurion Technologies sees Q4 revenue $3.3M-$3.7M, consensus $2.95M
“We are pleased with our results from the fourth quarter, where we grew revenue meaningfully quarter-over-quarter for the first time in more than one year as our new commercial strategy…
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced preliminary, unaudited results for the fourth quarte...
Allurion Technologies files to sell 5.99M shares of common stock for holders
17:25 EST Allurion Technologies (ALUR) files to sell 5.99M shares of common stock for holders
Allurion Technologies Registration statement: Registration Filing
Allurion Technologies filed a registration statement on January 9, 2026, providing details about a securities offering with the SEC.
Allurion reports initial results on Allurion Program, tirzepatide combination
Allurion Technologies (ALUR) announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. In total, 76 patients t...
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the...
Allurion Technologies Proxy statement: Proxy Filing
Allurion Technologies filed a proxy statement on November 25, 2025, providing details for shareholder voting and corporate governance matters.
Allurion Technologies Proxy statement: Proxy Filing
Allurion Technologies filed a proxy statement on November 24, 2025, providing details for shareholder voting and corporate governance matters.
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of a peer-reviewed, case-controlled ...